Icatibanto Cipla

Icatibant, the active ingredient in Icatibanto Cipla, is a bradykinin B2 receptor antagonist presented as an injectable solution for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in adult patients.

GNH USA supplies Icatibanto Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU‑GMP standards and provides cold‑chain logistics to ensure product integrity during global distribution. Customers receive regulatory documentation and batch release certificates with each shipment.

Icatibant is employed to manage hereditary angioedema, a condition characterized by excessive bradykinin‑mediated swelling. - Hereditary angioedema type I attacks: rapid reduction of swelling and pain. - Hereditary angioedema type II attacks: rapid reduction of swelling and pain. - Acute hereditary angioedema episodes in adults: shortens attack duration and severity. - Hereditary angioedema triggered by stress or trauma: fast symptom control. - Hereditary angioedema with normal C1‑esterase inhibitor levels: provides prompt relief of swelling.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema. - Nausea: occasional feeling of queasiness. - Headache: transient mild headache. Serious or Rare Side Effects: - Hypersensitivity reactions: anaphylaxis or severe rash. - Airway edema: swelling that may compromise breathing. - Thrombotic events: rare clot formation.

When using Icatibant, several precautions should be observed to ensure safe administration and maintain product quality. - Assess patient history: confirm diagnosis of hereditary angioedema and evaluate prior response to bradykinin antagonists. - Monitor for hypersensitivity: watch for signs of allergic reaction during and after injection. - Avoid use in patients with known hypersensitivity to icatibant or any excipients. - Consider renal or hepatic impairment: adjust monitoring as needed, although no dosage adjustment is routinely required. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines, primarily through pharmacodynamic or pharmacokinetic mechanisms. Major Interactions (Avoid): - ACE inhibitors: concurrent use may increase bradykinin levels and exacerbate angioedema. - Renin‑angiotensin system blockers (e.g., ARBs): similar risk of enhanced bradykinin‑mediated swelling. - Other bradykinin B2 antagonists: additive effects may increase adverse reactions. Moderate Interactions (Monitor Closely): - C1‑esterase inhibitor concentrates: may alter overall management of HAE; coordinate dosing. - Antihistamines or corticosteroids used for HAE attacks: monitor for overlapping side‑effect profiles. - Concomitant injectable biologics: assess injection site reactions.